The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging

Clinical Cancer Research

Volumn 11, Issue 2 I, 2005, Pages 529-536

  Jordan, Bénédicte F ^a,c   Runquist, Matthew ^a   Raghunand, Natarajan ^a   Gillies, Robert J ^a   Tate, Wendy R ^b   Powis, Garth ^b   Baker, Amanda F ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLPROPYL 2 IMIDAZOLYLDISULFIDE; ANTINEOPLASTIC AGENT; BOVINE SERUM ALBUMIN; CONTRAST MEDIUM; GADOLINIUM PENTETATE; IMIDAZOLE DERIVATIVE; PROTEIN INHIBITOR; PX 12; THIOREDOXIN; THIOREDOXIN 1 INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APPARATUS; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL STRAIN HT29; CONTRAST ENHANCEMENT; DRUG EFFECT; DRUG RESPONSE; FEMALE; MACROMOLECULE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; SCID MOUSE; TUMOR XENOGRAFT;

ALBUMINS; ANIMALS; CAPILLARY PERMEABILITY; COLONIC NEOPLASMS; CONTRAST MEDIA; DISULFIDES; FEMALE; GADOLINIUM DTPA; HUMANS; IMIDAZOLES; MAGNETIC RESONANCE IMAGING; MICE; MICE, SCID; OXIDATION-REDUCTION; THIOREDOXIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 12244275240     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Evelhoch JL, Gillies RJ, Karczmar GS, et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000;2:152-65.
2. Gillies RJ, Bhujwalla ZM, Evelhoch J, et al. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2000;2:139-51.
3. Brasch RC, Li KC, Husb JE, et al. In vivo monitoring of tumor angiogenesis with MR imaging. Acad Radiol 2000;7:812-23.
4. Neeman M, Provenzale JM, Dewhirst MW. Magnetic resonance imaging applications in the evaluation of tumor angiogenesis. Semin Radiat Oncol 2001;11:70-82.
5. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003;18:467-77.
6. Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signaling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;17;89:1889-95.
7. Buadu LD, Murakami J, Murayama S, et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 1996;200:639-49.
8. Hawighorst H, Weikel W, Knapstein PG, et al. Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. Clin Cancer Res 1998;4:2305-12.
9. Mayr NA, Hawighorst H, Yuh WT, Essig M, Magnotta VA, Knopp MV. MR microcirculation assessment in cervical cancer: correlations with histomorphological tumor markers and clinical outcome. J Magn Reson Imaging 1999;10:267-76.
10. Gossmann A, Helbich TH, Kuriyama N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002;15:233-40.
11. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
12. Kiessling F, Farhan N, Lichy MP, et al. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia 2004;6:213-23.
13. Ogan MD. Albumin labeled with Gd-DTPA: An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 1988;23:961.
14. Brasch R, Pham C, Shames D, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7:68-74.
15. Demsar F, Roberts TP, Schwickert HC, et al. A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution. Magn Reson Med 1997;37:236-42.
16. Su MY, Muhler A, Lao X, Nalcioglu O. Tumor characterization with dynamic contrast-enhanced MRI using MR contrast agents of various molecular weights. Magn Reson Med 1998;39:259-69.
17. Daldrup H, Shames DM, Wendland M, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998;171:941-9.
18. Gossmann A, Okuhata Y, Shames DM, et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhariced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media-preliminary experience. Radiology 1999;213:265-72.
19. Roberts TP, Turetschek K, Preda A, et al. Tumor microvascular changes to anti-angiogenic treatment assessed by MR contrast media of different molecular weights. Acad Radiol 2002;9 Suppl 2:S511-3.
20. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-84.
21. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000;36:1649-60.
22. Yonemura Y, Endo Y, Fujita H, et al. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res 1999;5:1823-9.
23. Gisselbrecht C, Likiec F, Marty M, et al. Cancer Chemother Pharmacol 1980;5:20.
24. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is upregulated in early premalignant stage of colorectal tumour progression. Int J Cancer 1999;81:845-50.
25. Wang G, Dong Z, Xu G, et al. The effect of antibody against vascular endothelial growth factor on tumor growth and metastasis. J Cancer Res Clin Oncol 1998;124:615-20.
26. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
27. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-64.
28. Dewhirst MW, Vinuya RZ, Ong ET, et al. Effects of bradykinin on the hemodynamics of tumor and granulating normal tissue microvasculature. Radiat Res 1992;130:345-54.
29. Ettinghausen SE, Puri RK, Rosenberg SA. Increased vascular permeability in organs mediated by the systemic administration of lymphokine activated killer cell and recombinant interleukin-1 in mice. J Natl Cancer Inst 1988;80:177-88.
30. Yuan F, Salehi HA, Boucher Y, Vasthare HS, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994;54:4565-8.
31. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A 2001;98:2604-9.
32. Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 2001;41:261-95.
33. Grippo JF, Tienrungroj W, Dahmer MK, Housley PR, Pratt WB. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin. J Biol Chem 1993;258:13658-64.
34. Qin J, Clore GM, Kennedy WP, Hutch JR, Gronenbom AM. Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF-κB. Structure 1994;3:289-97.
35. Ueno M, Masutani H, Jun Arai R, et al. Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 2001;274:35809-15.
36. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1α protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62:5089-95.
37. Abate C, Patel L, Rauscher FJ, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990;249:1157-61.
38. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998;17:2596-606.
39. Watson JA, Rumsby MG, Wolowacz RG. Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: thioredoxin inhibits protein kinase C-mediated phosphorylation of histone. Biochem J 1999;343:301-5.
40. Meuillet E, Mahadevan D, Berggren M, Coon A, Powis G. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: providing a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys 2004;429:123-33.
41. Chae HZ, Kim HJ, Kang SW, Rhee SG. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract 1999;45:101-12.
42. Nakamura H, Bai J, Nishinaka Y, et al. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer. Cancer Detect Prev 2000;24:53-60.
43. Nakamum H, Masutani H, Tagaya Y, et al. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 1992;69:2091-7.
44. Kakolyris S, Giatromanolakim A, Koukourakis M, et al. Thioredoxin expression is associated with lymph node status and prognosis in early operable non small cell lung cancer (NSCLC). Clin Cancer Res 2001;7:3087-91.
45. Grogan TM, Fenoglio-Prieser C, Zeheb R, et al. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 2000;31:475-81.
46. Raffel J, Bhattacharyya AB, Gallegos A, et al. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med 2002;142:46-51.
47. Kirkpatrick DL, Kuperus M, Dowdeswell M, et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 1998;55:987-94.
48. Kirkpatrick L, Dragovich T, Ramahathan R, et al. Results from phase I study of PX-12, a thioredoxin inhibitor in patients with advanced solid malignancies. Proc Am Assoc Clin Oncol 2004;22:217.
49. Baker A, Dragovich T, Tate WR, Kirkpatrick DL, Powis G. Pharmacodynamic proteomic studies of the thioredoxin-1 inhibitor PX-12 in mice and patients. Proc Am Assoc Clin Oncol 2004;22:3662.
50. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 2004;14:123-30.
51. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
52. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-43.
53. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 2001;3:143-53.
54. Luthman M, Holmgren A. Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry 1982;21:6628-33.
55. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen PE. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003;9:355-62.
56. Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891-9.
57. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16:407-22.
58. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002;94:1484-93.
59. Eppler SM, Combs DL, Henry TD, et al. A target mediated model to describe pharmacokinetic and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 2002;72:20-32.
60. Liu LX, Luo LH, Date T. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 2002;29:908-14.
61. Akaike WJ, Hayashida T, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 2001;92:439-51.
62. Patel JM, Zhang J, Block ER. Nitric oxide-induced inhibition of lung endothelial cell nitric oxide synthase via interaction with allosteric thiols: role of thioredoxin in regulation of catalytic activity. Am J Respir Cell Mol Biol 1996;15:410-9.
63. Rubartelli A, Bajetto A, Allavena G, Wollman E, Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 1992;267:24161-4.
64. Gasdaska JR, Berggren M, Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ 1995;6:1643-50.
65. Ballmer-Weber B, Dummer R, Kung E, Burg G, Ballmer P. Interleukin 2-induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer 1995;71:78-82.
66. Downie G, Ryan U, Hayes B, Friedman M. Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro. Am J Respir Cell Mol Biol 1992;7:58-65.
67. Takeuchi K, Okada M, Niida H, Okabe S. Dual effects of N-ethylmaleimide on ethanol-induced gastric lesions in rats. Dig Dis Sci 1991;36:870-9.
68. Turetschek K, Preda A, Floyd E, et al. MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. Acad Radiol 2002;2:S519-20.
69. Marzola P, Degrassi A, Calderan L, et al. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin Cancer Res 2004;10:739-50.
70. Beauregard DA, Pedley RB, Hill SA, Brindle KM. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 2002;15:99-105.
71. Daldrup-Link H, Okuhata Y, Wolfe A, et al. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. Microcirculation 2004;11:387-96.
72. DelProposto Z, LoRusso P, Latif Z, et al. MRI Evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature. Proc Am Soc Clin Oncol 2002;21:440.